Revel Pharmaceuticals key facts
as of Oct 2026- Developer of therapeutic enzymes designed for degrading molecular damage associated with aging.
- Revel Pharmaceuticals is valued at approximately $15.0M as of Oct 2026, set at its early-stage round, Mar 2022; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $14.7M across 3 recorded rounds; the latest was Early Stage VC ($5.8M) in Feb 2022.
- Notable investors include Gaingels, Formic Ventures, Starbloom Capital, Kizoo Technology Capital, Lifespan Extension Advocacy Foundation — 9 tracked in total.
- Revel Pharmaceuticals has filed 3 Form Ds with the SEC since 2020, most recently Mar 2022 ($5.8M sold to 3 investors).
- Status: Privately Held (backing).
Valued at $15.0M at its early-stage round, Mar 2022. Nothing has traded since.
- ·Watch Revel Pharmaceuticals: the Monday email on marks, rounds and moves
Revel Pharmaceuticals funding rounds
3 roundsRevel Pharmaceuticals valuation
Revel Pharmaceuticals was valued at $15 million at its early-stage round in Mar 2022. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Revel Pharmaceuticals raised?
Revel Pharmaceuticals has raised $14.7 million in total; 3 of its rounds are on record, from 2019 on. The largest on record was an $800,000 seed round in Mar 2021; the most recent was a $5.8 million early-stage round in Feb 2022.
Revel Pharmaceuticals has filed 3 Form Ds with the SEC since 2020, most recently in Mar 2022 ($5.8 million sold to 3 investors).
Revel Pharmaceuticals investors
9 investors are on record for Revel Pharmaceuticals, including Gaingels, Formic Ventures, Starbloom Capital and Kizoo Technology Capital. The early-stage round in Feb 2022 drew 3 investors.
About Revel Pharmaceuticals
Developer of therapeutic enzymes designed for degrading molecular damage associated with aging. The company's platform integrates enzyme discovery and engineering capabilities, encompassing design, optimization, and production of repair based catalytic treatments that clear toxic metabolites and protein modifications, enabling healthcare providers and researchers to target a range of age related diseases such as osteoarthritis, kidney disease, cardiovascular disease, skin aging, and complications of diabetes with molecular level repair.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2019
- Employees
- 7
- Website
- revelpharmaceuticals.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.